Mathew et al. reported that sorafenib promoted GVL activity in mice and humans through interleukin-15 (IL-15) production in FLT3-ITD-mutant leukemia cells, resulting in activation of the IRF7-IL-15 axis and metabolic reprogramming of leukemia-reactive T cells [17]. This evidence concerns the gene IL15 and leukemia.